Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Dokumenty

SML1051

Sigma-Aldrich

Bivalirudin trifluoroacetate salt

≥97% (HPLC)

Synonim(y):

D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-aspariginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine trifluoroacetate, Hirulog trifluoroacetate salt

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C98H138N24O33 · xC2HF3O2
Numer CAS:
128270-60-0
Masa cząsteczkowa:
2180.29 (free base basis)
Kod UNSPSC:
51111800
NACRES:
NA.77

Próba

≥97% (HPLC)

Postać

powder

kolor

white to off-white

Warunki transportu

wet ice

temp. przechowywania

−20°C

InChI

1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(150)69-22-14-37-120(69)94(151)57(99)41-53-16-8-6-9-17-53/h6-11,16-19,24-27,51-52,57-70,82,123H,5,12-15,20-23,28-50,99H2,1-4H3,(H2,100,124)(H,104,125)(H,105,127)(H,106,126)(H,107,140)(H,108,148)(H,109,128)(H,110,129)(H,111,142)(H,112,141)(H,113,145)(H,114,149)(H,115,150)(H,116,143)(H,117,147)(H,118,146)(H,119,144)(H,130,131)(H,132,133)(H,134,135)(H,136,137)(H,138,139)(H,154,155)(H4,101,102,103)/t52-,57+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,82-/m0/s1

Klucz InChI

OIRCOABEOLEUMC-GEJPAHFPSA-N

Działania biochem./fizjol.

Bivalirudin is a specific and reversible bivalent direct thrombin inhibitor. Bivalirudin specifically binds to both the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.
Bivalirudin trifluoroacetate salt is a synthetic peptide composed of 20 amino acids. It serves as an anticoagulant for patients with unstable angina undergoing coronary angioplasty.

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 3

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Slide 1 of 5

1 of 5

Heparin sodium salt from porcine intestinal mucosa Grade I-A, ≥180 USP units/mg

Sigma-Aldrich

H3393

Heparin sodium salt from porcine intestinal mucosa

Glutaraldehyde solution Grade I, 70% in H2O, specially purified for use as an electron microscopy fixative or other sophisticated use

Sigma-Aldrich

G7776

Glutaraldehyde solution

L-Cystine ≥98% (TLC), crystalline

Sigma-Aldrich

C8755

L-Cystine

vibrant-m

H0200000

Heparin sodium

Formaldehyde solution ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)

Sigma-Aldrich

252549

Formaldehyde solution

John C Rohloff et al.
Molecular therapy. Nucleic acids, 3, e201-e201 (2014-10-08)
Limited chemical diversity of nucleic acid libraries has long been suspected to be a major constraining factor in the overall success of SELEX (Systematic Evolution of Ligands by EXponential enrichment). Despite this constraint, SELEX has enjoyed considerable success over the
Matthew A Cavender et al.
Lancet (London, England), 384(9943), 599-606 (2014-08-19)
Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based anticoagulation regimen compared with a heparin-based anticoagulation regimen on ischaemic and bleeding outcomes. We searched Medline, the Cochrane
Uzoma N Ibebuogu et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions, 15(4), 275-285 (2015-03-19)
Diabetes mellitus (DM) is a pro-thrombotic state with enhanced thrombin generation and platelet reactivity. For most patients undergoing percutaneous coronary intervention (PCI), bivalirudin demonstrates efficacy comparable with that of heparin and glycoprotein IIb/IIIa inhibitors (GPIs). Yet, because of their pro-thrombotic
Gregg W Stone et al.
Journal of the American College of Cardiology, 65(1), 27-38 (2015-01-13)
In the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial, 3,602 patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) treated with bivalirudin had lower bleeding and mortality rates, but higher acute
Anthony A Bavry et al.
PloS one, 10(5), e0127832-e0127832 (2015-05-27)
Percutaneous coronary intervention with bivalirudin plus bail-out glycoprotein IIb/IIIa inhibitors has been shown to be as effective as unfractionated heparin plus routine glycoprotein IIb/IIIa inhibitors in preventing cardiac ischemic events, but with a lower bleeding risk. It is unknown whether
Wyświetl wszystkie powiązane dokumenty

Produkty

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej